Purple Biotech
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, whi… Read more
Purple Biotech (PPBT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.031x
Based on the latest financial reports, Purple Biotech (PPBT) has a cash flow conversion efficiency ratio of -0.031x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.01 Million) by net assets ($32.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Purple Biotech - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Purple Biotech's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Purple Biotech Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Purple Biotech ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inepar S.A. Indústria e Construções
SA:INEP3
|
0.035x |
|
Samyang Foods Co. Ltd.
KQ:003230
|
N/A |
|
Eros International Media Limited
NSE:EROSMEDIA
|
-0.061x |
|
PT Platinum Wahab Nusantara Tbk
JK:TGUK
|
-0.021x |
|
Leon Fuat Bhd
KLSE:5232
|
0.033x |
|
Xplus SA
WAR:XPL
|
0.059x |
|
BIOSYNEX INH. EO-10
F:0DL
|
N/A |
|
OPTIBIOTIX HLTH PLC LS-02
F:OB3
|
N/A |
Annual Cash Flow Conversion Efficiency for Purple Biotech (2013–2024)
The table below shows the annual cash flow conversion efficiency of Purple Biotech from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $32.91 Million | $-14.37 Million | -0.437x | +24.86% |
| 2023-12-31 | $34.30 Million | $-19.93 Million | -0.581x | -63.50% |
| 2022-12-31 | $47.10 Million | $-16.73 Million | -0.355x | -53.50% |
| 2021-12-31 | $65.11 Million | $-15.07 Million | -0.231x | -52.67% |
| 2020-12-31 | $79.75 Million | $-12.09 Million | -0.152x | +70.49% |
| 2019-12-31 | $10.86 Million | $-5.58 Million | -0.514x | +33.32% |
| 2018-12-31 | $11.00 Million | $-8.48 Million | -0.771x | +23.24% |
| 2017-12-31 | $8.59 Million | $-8.63 Million | -1.004x | -114.60% |
| 2016-12-31 | $13.38 Million | $-6.26 Million | -0.468x | -33.35% |
| 2015-12-31 | $9.43 Million | $-3.31 Million | -0.351x | +94.01% |
| 2014-12-31 | $773.00K | $-4.53 Million | -5.855x | -1181.82% |
| 2013-12-31 | $-946.00K | $-512.00K | 0.541x | -- |